Copy Link Print Information

Acalabrutinib

(Synonyms: Calquence; ACP-196)
35 Cited Publications
Customer Review

Based on 35 publication(s) in Google Scholar

Acalabrutinib (ACP-196) is an orally active, irreversible, and highly selective second-generation BTK inhibitor. Acalabrutinib binds covalently to Cys481 in the ATP-binding pocket of BTK. Acalabrutinib demonstrates potent on-target effects and efficacy in mouse models of chronic lymphocytic leukemia (CLL). Acalabrutinib can be used for CLL research. Acalabrutinib is a click chemistry reagent, itcontains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

For research use only. We do not sell to patients.

  • Purity: 99.86%
  • CAS No.: 1420477-60-6
  • Formula: C26H23N7O2
  • Molecular Weight:465.51
  • Storage:
    Powder   -20°C, 3 years , 4°C, 2 years ; In solvent   -80°C, 1 year , -20°C, 6 months
  • Acalabrutinib Chemical Structure
    Acalabrutinib Chemical Structure
  • Experimental Validation Results for Acalabrutinib
  • Experimental Validation Results for Acalabrutinib
  • Experimental Validation Results for Acalabrutinib
  • Experimental Validation Results for Acalabrutinib
  • Experimental Validation Results for Acalabrutinib
CAS No.: 1420477-60-6
Size
Price
Stock
Quantity
Amount: USD 0.00
Please select quantity
or
or

* Please select Quantity before adding items.

To place orders, for customer services and technical support, please contact: MedChemExpress USA

Tel: 609-228-6898 E-mail: [email protected] [email protected]

Data Download
Other Forms of Acalabrutinib:

To place orders, for customer services and technical support, please contact:

609-228-6898
[email protected] [email protected]
Find Your Local Distributor Your local distributor: Hycultec GmbHHycultec
  • Biological Activity
  • Chemical Information
  • Solvent & Solubility
  • Purity & Documentation
  • References
  • Help & FAQs
You May Still Need
Top Publications Citing

Use of MCE Products

Publications Citing Use of MedChemExpress (MCE) Acalabrutinib

More
Customer Validation & Images
Flow CytometryCell Imaging/StainingELISAHistological Imaging/Staining
  • Flow Cytometry
  • Cell Imaging/Staining
  • ELISA
  • Histological Imaging/Staining
  • Flow Cytometry
Keywords
100 mg

Get Quote In-stock

Please select quantity
Amount: USD 0.00
Sign in to MedChemExpress Sign In
Register
Sign in to MedChemExpress
Register New Account

At least 6 characters

Personalize your experience, you are currently not signed in. For a better experience, please create an online profile, you can:

Obtain points redemption prizes
Check out faster
Add multiple shipping locations
View orders
Assay Types
  • Acalabrutinib Chemical Structure
    Acalabrutinib Chemical Structure
    1/16
  • 1/16

    Acalabrutinib purchased from MedChemExpress. Usage Cited in: Sci Adv. 2025 Apr 18;11(16):eadt8199. [Abstract]

    Customer Validation
     Aged mice were given vehicle or Acalabrutinib (0.15 mg/mL, drinking water administration) for 21 days (n = 10 per group, pooled from two experiments). Flow cytometry plots; right, FO B cell and ABCs (CD21loCD11c+) percentages among mature B cells.

  • 1/16

    Acalabrutinib purchased from MedChemExpress. Usage Cited in: Sci Adv. 2025 Apr 18;11(16):eadt8199. [Abstract]

    Customer Validation
     Aged mice were given vehicle or Acalabrutinib (0.15 mg/mL, drinking water administration) for 7 days. Each group was tested in two experiments (n = 4 or 3 per experiment). The percentage of Ki67+ FO B cells and ABCs was compared.

  • 1/16

    Acalabrutinib purchased from MedChemExpress. Usage Cited in: Sci Adv. 2025 Apr 18;11(16):eadt8199. [Abstract]

    Customer Validation
     Autoantibodies against histone, dsDNA, and Sm/RNP in vehicle- or Acalabrutinib (0.15 mg/mL, drinking water administration, 3 weeks)-treated mice serum were tested by enzyme-linked immunosorbent assay (ELISA). OD, optical density.

  • 1/16

    Acalabrutinib purchased from MedChemExpress. Usage Cited in: Sci Adv. 2025 Apr 18;11(16):eadt8199. [Abstract]

    Customer Validation
     Representative renal immunostaining of immunoglobulin deposition in kidneys, stained with anti-IgG, and bright-field imaging from vehicle-treated WT and vehicle- or Acalabrutinib (0.15 mg/mL, drinking water administration, 3 weeks)-treated bm12-induced lupus mice. Scale bars, 50 μm.

  • 1/16

    Acalabrutinib purchased from MedChemExpress. Usage Cited in: Sci Adv. 2025 Apr 18;11(16):eadt8199. [Abstract]

    Customer Validation
     Schematic for Acalabrutinib treatment from day 0. CD19+ B cells were cultured with R848, IL-21, anti-Ig, and BAFF supplemented with Acalabrutinib (10 μM, 3 days) or DMSO for 3 days. Representative flow cytometry plots of CD11c and T-bet expression in each group on day 3 and the frequency of CD11c+T-bet+ ABCs among live B cells.

  • Acalabrutinib